CORBUS PHARMACEUTICALS HLDGS's ticker is CRBP and the CUSIP is 21833P103. A total of 113 filers reported holding CORBUS PHARMACEUTICALS HLDGS in Q4 2020. The put-call ratio across all filers is 0.88 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $88,000 | +57.1% | 44,766 | +0.3% | 0.00% | – |
| Q4 2020 | $56,000 | -30.0% | 44,648 | -0.0% | 0.00% | – |
| Q3 2020 | $80,000 | -76.5% | 44,659 | +10.2% | 0.00% | -100.0% |
| Q2 2020 | $340,000 | +66.7% | 40,520 | +4.0% | 0.00% | +100.0% |
| Q1 2020 | $204,000 | +0.5% | 38,974 | +4.9% | 0.00% | 0.0% |
| Q4 2019 | $203,000 | +10.9% | 37,171 | -0.8% | 0.00% | 0.0% |
| Q3 2019 | $183,000 | -30.2% | 37,482 | -0.7% | 0.00% | 0.0% |
| Q2 2019 | $262,000 | +8.3% | 37,744 | +8.2% | 0.00% | 0.0% |
| Q1 2019 | $242,000 | +26.0% | 34,869 | +6.2% | 0.00% | 0.0% |
| Q4 2018 | $192,000 | -23.2% | 32,841 | -0.8% | 0.00% | 0.0% |
| Q3 2018 | $250,000 | +52.4% | 33,093 | +1.8% | 0.00% | 0.0% |
| Q2 2018 | $164,000 | -14.6% | 32,497 | +3.5% | 0.00% | 0.0% |
| Q1 2018 | $192,000 | -17.2% | 31,396 | -3.8% | 0.00% | 0.0% |
| Q4 2017 | $232,000 | +9.4% | 32,650 | +10.0% | 0.00% | 0.0% |
| Q3 2017 | $212,000 | +22.5% | 29,694 | +8.1% | 0.00% | 0.0% |
| Q2 2017 | $173,000 | – | 27,474 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 5,045,870 | $1,273,000 | 0.73% |
| ETF MANAGERS GROUP, LLC | 7,062,485 | $1,787,000 | 0.05% |
| Ikarian Capital, LLC | 862,527 | $217,000 | 0.04% |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | 457,209 | $115,000 | 0.02% |
| Platform Technology Partners | 33,750 | $9,000 | 0.01% |
| PINNACLE ASSOCIATES LTD | 910,006 | $230,000 | 0.01% |
| CJM Wealth Advisers, Ltd. | 30,465 | $7,683 | 0.01% |
| Mirae Asset Global Investments Co., Ltd. | 4,029,171 | $1,016,000 | 0.00% |
| Vident Investment Advisory, LLC | 267,612 | $67,000 | 0.00% |
| Aries Wealth Management | 15,400 | $4,000 | 0.00% |